

3050 Spruce Street Saint Louis, Missouri 63103 USA Telephone (800) 325-5832 (314) 771-5765 Fax (314) 286-7828 email: techserv@sial.com sigma-aldrich.com

ProductInformation

a₂-Macroglobulin from human plasma

Product Number **M 6159** Storage Temperature –20 °C

Product Description

 α_2 -Macroglobulin inhibits all classes of endoproteases. The protease cleaves the α_2 -macroglobulin at a "bait" sequence changing the conformation of the α_2 -macroglobulin. A thioester bond is hydrolyzed that mediates the covalent binding of α_2 -macroglobulin to the protease.¹

 α_2 -Macroglobulin is found in normal plasma at a concentration of 220-230 mg/dl accounting for 3-5% of the total plasma protein. Conditions such as kidney and liver diseases, and diabetes can elevate this level.² The protease/ α_2 -macroglobulin balance plays an important role in mediating inflammation-associated tissue destruction. Serum levels of α_2 -macroglobulin and protease/ α_2 -macroglobulin complexes are increased in patients with sepsis, emphysema, periodontitis, rheumatoid arthritis, and other inflammatory diseases. It is hypothesized that the oxidant inactivation of α_2 -macroglobulin contributes to tissue destruction in inflammation. α_2 -Macroglobulin has been implicated as a genetic risk factor for lateonset Alzheimer's disease. Activated α_2 -macroglobulin enhances the clearance of soluble α/β -amyloid via

low-density lipoprotein receptor-related protein in cortical neurons, but has no effect on secreted or full-length amyloid precursor protein levels.² α_2 -Macroglobulin accounts for approximately half of the anti-thrombin activity in plasma.³ Prostate Specific Antigen, a glycoprotein of the glandular kallikrein family, exists in free and α_2 -macroglobulin-bound forms. The ratios of free to inhibitor-bound forms may prove valuable in the diagnosis of prostate cancer.⁴

Molecular mass:⁵⁻⁷ 725 kDa.

The molecule is a tetramer with four identical subunits with molecular weights of 179 kDa.⁸ Upon binding to a protease, the 179 kDa subunit is cleaved into two 85 kDa fragments as determined by SDS-PAGE under reducing conditions.⁵⁻⁷

3.6%
1.8%
2.9%
0.1%
8.4%

Isoelectric point (pl):¹⁰ 5.0-5.2.

Protease inhibition:^{11,12}

Proteases inhibited or trapped by α_2 -macroglobulin	
acrosin	arvin
bromelain	calpain
cathepsins B, D, G, H, and L	chymosin
chymotrypsin	clostripain
leukocyte and vertebrate collagenase	ficin
leukocyte and pancreatic elastase	papain
plasma kallikrein	medullasin
plasmin	thermolysin
lysosomal proteases	trypsin
subtilisins A and B	
serine and metalloproteinases from Crotalis atrox	

This product is prepared from human plasma by a modification of a published procedure.⁵ All plasma was tested for and found to be negative for HB_SAg and the antibody to HIV. The product is supplied as a powder lyophilized from a solution containing 100 mg/ml protein and 0.02 M Tris, 0.13 M glycine, pH 8.0, and 0.08 M trehalose.

Purity: minimum 98% (SDS-PAGE)

<u>Activity</u>: This product is a preparation of the intact protein with proteolytic inhibitory activity. One mg of protein will inhibit a minimum of 10 μ g of trypsin with an activity of 10,000 BAEE units/mg protein.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

 α_2 -Macroglobulin is soluble in water (10 mg-protein/ml), yielding a clear, colorless solution.

Storage/Stability

The lyophilized powder is stable for at least 2 years when stored at -20 °C.

Upon reconstitution, store in aliquots at –20 °C and avoid freeze/thaw cycles. Frozen solutions have been found to maintain full activity for at least one year. Refrigerated solutions have been found to maintain activity for at least three days. α_2 -Macroglobulin is denatured under acidic conditions (below pH 4) with dissociation into two halves.¹¹ Mild reduction by 1 mM DTT causes reversible denaturation into four inactive, native subunits.¹¹

References

- 1. Poller, W., et. al., Hum. Genet., 88, 313-319 (1992).
- 2. Allen, P.D, *et.al.*, in Plasma Protein. Analytical and preparative techniques, Blackwell Science (Oxford, UK: 1977), pp. 190-194.
- 3. Rimon, A., J. Biol. Chem., **241**, 5102 (1966).
- 4. Ambruster, D.A., Clin. Chem., **39**, 181 (1993).
- 5. Swenson, R., and Howard, J., J. Biol. Chem., **254**, 4452 (1979).
- Hall, P., and Roberts, R., Biochem. J., **173**, 27 (1978).
- 7. Virca, G., et al., Anal. Biochem., 89, 274 (1978).
- 8. Sottrup-Jensen, L., *et al.*, J. Biol. Chem., **259**, 8318 (1984).
- 9. Shultz, N., Biochem. Z., 329, 490 (1958).
- 10. Barrett, A.J., et. al., Biochem. J., 181, 401 (1979).
- 11. Barrett, A.J., Meth. Enzymol., 80, 737 (1981).
- Handbook of Enzyme Inhibitors, 2nd ed., Zollner, H., VCH Verlagsgesellschaft mbH (Weinheim, Federal Republic of Germany: 1993), p. 827.
- 13. Qiu, Z., *et al.*, J. Neurochem., **73**, 1393-1398 (1999).

CR/RBG/MAM 02/05-1

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.